Navigation Links
Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony
Date:1/17/2011

LONDON, Jan. 17, 2011 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Chiltern has won multiple awards at the PharmaTimes Annual Awards 2010 ceremony held at the Park Plaza Riverbank Hotel in London. The competition, established in 1999, celebrates the competence and ability of top clinical research professionals.

Glenn Kerkhof, Chiltern CEO, congratulates all of Chiltern's Award Winners and Finalists. "I am very proud of every Chiltern colleague nominated for an award. They put their best forward each and every day for our clients and their dedication to being the best is evident in all they do. These achievements of the award winners reflect Chiltern's commitment to deliver expert, high quality services around the world and I couldn't be happier that they have received the recognition that is so well-deserved."

Chiltern Award WinnersClinical Research Associate of the Year Gold Award: Helen Chester, Chiltern Resourcing Solutions CRA outsourced to Roche

Clinical Research Associate of the Year Silver Award: Dawn Skingle, Sr. Clinical Research Associate

Clinical Research Team of the Year Bronze Award: Daniel Lowman, Sr. Clinical Research Associate, Kate Backhouse, Clinical Research Associate 2, Jonathan Kinnell, Sr. Manager, Clinical Monitoring, Mark Williams, Clinical Trainer, Europe

Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.For More Information Contact:Natalie Chong

Susan OjanenChiltern International Ltd.

Chiltern International Inc.171 Bath Road

1241 Volunteer ParkwaySlough

Suite 950Berkshire SL1 4AA

Bristol, TN 37620UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Fax: +44 (0) 1753 511 116

Fax: +1 (423) 968 3567Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
2. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
3. European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends
4. Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program
5. Sales of Revlimid and the Launch of Several Premium-Priced Emerging Therapies Will Drive Robust 7.2 Percent Annual Growth in the Multiple Myeloma Drug Market
6. Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
7. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
8. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
9. 34-Year-Old Alabama Woman Crosses the Finish Line to Join Team COPAXONE® and Raise Awareness about Multiple Sclerosis
10. New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group
11. New Trauma Market Research Data Covering Multiple Geographies Released by Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):